Gynecologic Surgery
Conference Coverage
Minimally Invasive Cytoreductive Approach Comparable to Open Surgery for Ovarian Cancer
There were no differences in survival for patients with complete gross resections who underwent interval debulking via laparoscopy/robotics or...
Conference Coverage
Non-Radical Surgery a Win-Win for Early Cervical Cancer
Researchers assessed changes in bladder function and sexual function, and other functional outcomes of QOL in patients who had a non-radical...
Latest News
High Cesarean Rates Persist in Obesity Despite Standardized Protocols
Data suggest physiologic differences as potential contributors to increased cesarean rates in patients with obesity.
Latest News
The Struggle to Provide Gender-Affirming Care to Youth
Gender-affirming care has been restricted in about half of US states and there have been increasing threats of violence against physicians,...
From the Journals
Hemorrhage-control device holds up in real-world review
Timely use of a new vacuum-induced bleeding control device may improve maternal outcomes.
Latest News
Despite effective therapies, fibroid care still lacking
The biggest challenge is to ensure that women can take advantage of the newer minimally invasive therapies.
From the Journals
Surgery approach may improve survival in advanced ovarian cancer
From the Journals
New studies inform best practices for pelvic organ prolapse
Addition of estrogen in apical/uterovaginal prolapse repair showed no benefits; Manchester technique outperforms sacrospinous hysteropexy for...
From the Journals
Dural-puncture epidural drives faster conversion to cesarean anesthesia
Patients randomized to dural epidural also showed a higher quality of epidural blockade for surgical delivery.
Conference Coverage
Surgical de-escalation passes clinical test in low-risk cervical cancer
‘Practice-changing’ results could reduce long-term survivor effects among qualifying patients.
Conference Coverage
Wireless neurostimulation safe for urge incontinence
More than three-quarters of the women who received the device responded to therapy at 1 year, and 84.6% of the patients showed improvement.